NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay Cancer Relapse

NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay Cancer Relapse
3.3
(3)

The (NCI) has awarded to support the work of a researchercancer relapse in people with multiple myeloma.

This form of blood cancer causes malignant cancer cells to accumulate in the bone marrow, the soft spongy tissue found inside bones, progressively damaging the bones and causing them to become weaker and more prone to fractures.

At the same time, by living inside bones, the myeloma cells are harder to eliminate — the bone tissues shield them from cancer-killing therapies. That “protection” allows these cells to remain inside bones in a dormant state for long periods of time, until external conditions are ideal for them to become active and cause a relapse.

The awardee,

In his research, will investigate the therapeutic potential of two different drugs: one designed to break the interaction between myeloma cells and the bone microenvironment; and the other to enhance bone rebuilding in patients with the disease.

“We will study the effectiveness of a novel bone-targeted drug designed by our lab to interrupt the signaling pathway between cancer cells and tumor’s microenvironment to decrease tumor growth and relapse of the disease,” he said.

The second drug, which has shown promising efficacy at restoring bone mass in patients with osteoporosis, uses an antibody to neutralize sclerostin, a protein that normally prevents bone formation and is overly produced in bones containing myeloma cells.

“We will test whether a combination of those two bone-directed agents given together decreases tumor growth, prevents or delays relapse and encourages bone repair,” the researcher said.

According to Delgado-Calle, next steps in the project include investigating how both drugs interact with other treatments commonly used to treat myeloma patients, such as chemotherapy and radiation therapy, and assessing their effects on animal models.

He also added that because these drugs specifically target bone tissues, the toxicity they might pose to other tissues and organs could be reduced. These therapies may be useful to treat other types of cancer that often invade bones tissues at later stages of development, such as breast or prostate cancers.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 145
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • NCI Award, bone therapy
  • ide-cel granted FDA priority review
  • FDA hold, UCARTCS1A
  • CYAD-211

How useful was this post?

Click on a star to rate it!

Average rating 3.3 / 5. Vote count: 3

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?